Management of NRTI Resistance
|
|
- Gordon Johns
- 5 years ago
- Views:
Transcription
1 NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington Last Updated: June 8, 2015 This presentation is intended for educational use only, and does not in any way constitute medical consultation or advice related to any specific patient.
2 NRTI Resistance: Outline Mechanism of NRTI Resistance M184V Mutation Thymidine Analog Mutations (TAMs) K65R Mutation
3 RESISTANCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Mechanisms of NRTI Resistance
4 HIV Reverse Transcription Conversion of HIV RNA to HIV DNA HIV RNA Reverse Transcription Reverse Transcriptase HIV DNA
5 HIV Reverse Transcription HIV DNA HIV RNA Reverse Transcriptase
6 HIV Reverse Transcription Nucleotides (human) HIV DNA HIV RNA Reverse Transcriptase
7 HIV Reverse Transcription Nucleotides (human) Primer HIV DNA HIV RNA Template Reverse Transcriptase
8 Inhibition of HIV Reverse Transcription NRTI Mechanism of Action Nucleotides NRTI Primer HIV DNA (1) Incorporation of NRTI (2) Primer Blocking HIV RNA Template Reverse Transcriptase
9 Inhibition of HIV Reverse Transcription NRTI Mechanism of Action Nucleotides NRTI HIV DNA Chain Termination HIV RNA Reverse Transcriptase
10 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Biochemical Mechanisms of Resistance 1. Discrimination Pathway Decreased incorporation of NRTIs Process favors authentic nucleotides over NRTIs 2. Nucleotide Excision Pathway Enhanced removal of incorporated NRTI Results from phosphorolytic reaction that leads to primer unblocking From: Shafer RW, Schapiro JW. AIDS Rev. 2008;10:67-84.
11 Biochemical Mechanisms of NRTI Resistance (1) Discrimination Pathway Enhanced discrimination against NRTIs and decreased incorporation of NRTIs in favor of host nucleotides Nucleotides NRTI Enhanced Incorporation of Host Nucleotides Decreased Incorporation of NRTI HIV DNA HIV RNA Reverse Transcriptase
12 Biochemical Mechanisms of NRTI Resistance (2) Excision Pathway Excision of incorporated NRTI by promoting pyrophosphorolysis (primer unblocking) Nucleotides NRTI Excision (Primer Unblocking) HIV DNA Reverse Transcriptase HIV RNA
13 RESISTANCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Common NRTI Resistance Mutations
14 Wild Type HIV-1: NRTIs Wild Type HIV Tenofovir Zidovudine Stavudine Abacavir Didanosine Lamivudine Emtricitabine High-Level Resistance Low-Level Resistance Increased Susceptibility
15 Case History A 33-year-old woman develops virologic failure while taking tenofovir-emtricitabine-efavirenz (Atripla). Recent HIV RNA levels were 468 copies/ml and 1482 copies/ml. A baseline genotype showed no mutations, but genotype ordered after virologic failure shows M184V and K103N mutations. In constructing a new antiretroviral regimen, is there value in maintaining the M184V mutation?
16 M184V Mutation Frequently Emerges with Virologic Failure Initial PI-Based and NNRTI-Based Regimens 6 NNRTI-Based Studies 6 PI-Based Studies Patients (%) Patients (%) Major NNRTI 0.03 M184V Any TAM 0.27 K65R Major PI M184V Any TAM K65R Mutation Mutation NNRTI-Based Studies: Study 903, Study 934, COMBINE PI-Based Studies ACTG 5142, Study 089, MONARK, Study 863, ESS4001 Source: Gupta R, et al. Clin Infect Dis. 2008;47:
17 Response to Lamivudine Monotherapy HIV RNA Levels Before and After M184V Mutation 0.5 Change in HIV RNA (Log 10 ) Lamivudine 300 mg BID only Lamivudine Resistance (M184V) Treatment time (weeks) Source: Eron JJ, et al. N Engl J Med 1995;333:
18 M184V/I Mutation M184V/I Mutation Tenofovir Zidovudine Stavudine Abacavir Didanosine Lamivudine Emtricitabine High-Level Resistance Low-Level Resistance Increased Susceptibility
19 M184V/I Mutation Score Mutation Scoring: Stanford HIV Drug Resistance Database RT 3TC ABC AZT D4T DDI FTC TDF M184V/I Total Source: Stanford University: HIV Drug Resistance Database (accessed 6/9/2015)
20 Lamivudine Monotherapy versus Treatment Interruption in Patients with M184V Mutation Patients on failing therapy requesting treatment interruption CD4 > 500 cells/mm 3 HIV RNA > 1,000 copies/ml M184V Mutation n = 58 All ARV Meds Discontinued n = 29 Lamivudine 300 mg qd n = 29 Resume Therapy - CD4 < CDC B or C Event Source: Castagna A, et al. AIDS. 2006;20:
21 Lamivudine Monotherapy versus Treatment Interruption in Patients with M184V Mutation Parameter at Week 48 Lamivudine Continued All ARVs Stopped Change in CD4 Cell Count Change in CD4 Cell % -3% -8%* Change in HIV RNA log log** > Grade 3 Adverse Events 7% 31% *** Immunologic/Clinical Failure 41% 69% *P = 0.001; **P = 0.002; *** P < Source: Castagna A, et al. AIDS. 2006;20:
22 Why Maintain the M184V/I Mutation? Lamivudine and emtricitabine maintain partial viral activity Increases susceptibility to tenofovir, zidovudine, and stavudine Slows emergence of resistance to tenofovir, zidovudine, and stavudine Associated with reduced virologic fitness
23 Case History A 49-year-old man presents as a new patient to the clinic after recently moving. He has a long history of taking antiretroviral therapy, beginning in the early 1990s. He has been off antiretroviral therapy for 6 months. The most recent genotype shows the following mutations: RT: M41L, K103N, Y181C, M184V, L210W, T215Y Protease: D30N, I54L, and L90M What is the significance of the RT mutations M41L, L210W, and T215?
24 Thymidine Analog Mutations (TAMs) Thymidine Analogs Thymidine Analog Mutations Zidovudine Stavudine M41L D67N K70R L210W T215YF K219QE
25 M184V/I and Multiple TAMs M184V/I + 3TAMs (M41L, L210W, T215Y) Tenofovir Zidovudine Stavudine Abacavir Didanosine Lamivudine Emtricitabine High-Level Resistance Low-Level Resistance Increased Susceptibility
26 M184V/I and Multiple TAMs (M41L, L210W, T215Y) Mutation Scoring: Stanford HIV Drug Resistance Database RT 3TC ABC AZT D4T DDI FTC TDF M41L M184V L210W T215Y T215Y + M41L T210W + T215Y T210W + M41L Total Source: Stanford University: HIV Drug Resistance Database (accessed 11/18/2014)
27 Thymidine Analog Mutations (TAMs) Wild Type HIV Zidovudine or Stavudine M41L D67N K70R L210W T215Y/F K219Q/E Thymidine Analog Mutations (TAMs)
28 Distinct TAM Pathways to Resistance Zidovudine or Stavudine Type-1 TAM Pattern M41L L210W T215Y Type-2 TAM Pattern D67N K70R T215F K219Q/E Source: Shafer RW, Schapiro JM. AIDS Rev. 2008;10:67-84.
29 Distinct TAM Pathways to Resistance Zidovudine or Stavudine Type-1 TAM Pattern M41L L210W T215Y Higher level of zidovudine resistance Higher level NRTI cross-resistance Less decrease in resistance with M184V Type-2 TAM Pattern D67N K70R T215F K219Q/E Lower level of zidovudine resistance Lower level of NRTI cross-resistance More decrease in resistance with M184V Source: Shafer RW, Schapiro JM. AIDS Rev.2008;10:67-84.
30 Resistance Pathway with Thymidine Analog + Lamivudine Zidovudine + Lamivudine or Stavudine + Lamivudine M184V/I Type-1 TAM Pattern M41L L210W T215Y Type-2 TAM Pattern D67N K70R T215F K219Q/E
31 Case History A 56-year-old man with a history of extensive antiretroviral therapy and resistance presents to discuss a new regimen. His genotype has multiple mutations, including a K65R mutation. What is the impact of the K65R mutation on drugs in the NRTI class?
32 K65R Mutation K65R Mutation Tenofovir Zidovudine Stavudine Abacavir Didanosine Lamivudine Emtricitabine High-Level Resistance Low-Level Resistance Increased Susceptibility
33 K65R Mutation Score Mutation Scoring: Stanford HIV Drug Resistance Database RT 3TC ABC AZT D4T DDI FTC TDF K65R Total Source: Stanford University: HIV Drug Resistance Database (accessed 6/9/2015)
34 Resistance Pathway with Tenofovir + Emtricitabine Tenofovir + Emtricitabine M184V/I K65R
35 Resistance Pathway with Abacavir + Lamivudine Abacavir + Lamivudine M184V/I L74V K65R
36 M184V/I + K65R Mutations M184V/I + K65R Mutations Tenofovir Zidovudine Stavudine Abacavir Didanosine Lamivudine Emtricitabine High-Level Resistance Low-Level Resistance Increased Susceptibility
37 M184V/I + K65R Mutation Score Mutation Scoring: Stanford HIV Drug Resistance Database RT 3TC ABC AZT D4T DDI FTC TDF K65R M184V K65R + M184V Total Source: Stanford University: HIV Drug Resistance Database (accessed 11/18/2014)
38 RESISTANCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS NRTI Resistance: Summary
39 NNRTI Resistance: Summary Two major resistance mechanisms: discrimination and excision M184V common and reduces emtricitabine/lamivudine activity Once M184V develops, maintaining mutation has advantages Multiple TAMs cause broad NRTI resistance K65R has major impact on NRTIs except for zidovudine In most NRTI resistance pathways, M184V develops early
40 Questions
NNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington Last Updated:
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationResistance to Integrase Strand Transfer Inhibitors
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Resistance to Integrase Strand Transfer Inhibitors David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationEvaluation and Management of Virologic Failure
National HIV Curriculum PDF created November 3, 2018, 12:26 am Evaluation and Management of Virologic Failure This is a PDF version of the following document: Section 1: Antiretroviral Therapy Topic 5:
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationWhole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy
Whole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy K El Bouzidi 1,, RP Datir 1, V Kwaghe 3, S Roy 1, D Frampton
More informationDifferentiating emtricitabine (FTC) from lamivudine (3TC): what a fine-tuning of antiretroviral therapy might entail
HAART, HIV correlated pathologies and other infections Renato Maserati Differentiating emtricitabine (FTC) from lamivudine (3TC): what a fine-tuning of antiretroviral therapy might entail Corresponding
More informationAntiviral Therapy 2011; 16: (doi: /IMP1851)
Antiviral Therapy 2011; 16:925 929 (doi: 10.3851/IMP1851) Short communication Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationClinical skills building - HIV drug resistance
Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationThe Use of Resistance Testing in HIV
The Use of Resistance Testing in HIV Dushyantha Jayaweera, M.D., M.R.C.O.G., F.A.C.P. Professor in Clinical Medicine Division of Infectious Diseases University of Miami Miller School of Medicine Viral
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationHepatitis B Case Studies
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationViral Resistance with Topical RT-Microbicides. Ian McGowan MD PhD FRCP David Geffen School of Medicine Los Angeles
Viral Resistance with Topical RT-Microbicides Ian McGowan MD PhD FRCP David Geffen School of Medicine Los Angeles verview What antiretrovirals (ARV) are being considered as candidate microbicides? How
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationDTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone
DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone Aboud M, 1 Brites C, 2 Lu H, 3 Supparatpinyo K, 4 Hercilla L, 5 Sievers J, 1 Nascimento MC, 1 Hopking J, 6 Underwood
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationGenotypic Resistance in HIV-infected Patients Failing a d4t/3tc/nvp Regimen
Original Article Genotypic Resistance in HIV-infected Patients Failing a d4t/3tc/nvp Regimen Somnuek Sungkanuparph, M.D.* Weerawat Manosuthi, M.D.* Sasisopin Kiertiburanakul, M.D.* Wasun chantratita, Ph.D.**
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationPerspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation
Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Resistance testing has emerged as an important tool for antiretroviral management. Research continues to refine
More informationNNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER NNRTI Resistance Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared by: Brian
More informationHistory (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11
(August 2010) Therapy for Experienced Patients Hiroyu Hatano, MD, MHS Assistant Professor of Medicine University of California San Francisco Medical Management of AIDS December 2011 42M HIV (CD4=450, VL=6250,
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationAntiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V
Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V Christian Callebaut, PhD Gilead Sciences, Foster City, CA, USA HIV DART AND EMERGING VIRUSES 12/08/2016
More informationARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za
ARV Mode of Action Mode of Action Mode of Action - NRTI Mode of Action - NNRTI Mode of Action - Protease Inhibitors Mode of Action - Integrase inhibitor Mode of Action - Entry Inhibitors Mode of Action
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationBecause accurate and reproducible phenotypic susceptibility
BRIEF REPORT: CLINICAL SCIENCE Comparison of the Precision and Sensitivity of the Antivirogram and PhenoSense HIV Drug Susceptibility Assays Jie Zhang, MS,* Soo-Yon Rhee, MS,* Jonathan Taylor, PhD, and
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationHIV Drug Resistance among Adolescents and Young Adults Failing HIV Therapy in Zimbabwe
HIV Drug Resistance among Adolescents and Young Adults Failing HIV Therapy in Zimbabwe V Kouamou 1, J Manasa 1, D Katzenstein 1, A McGregor 1, CE Ndhlovu 1 & AT Makadzange 1. 1 University of Zimbabwe Introduction
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationHIV 101: Fundamentals of HIV Infection
HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question 12/6/2017
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop 12/9/16. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationI m B m. 1 f ub I B. D m B. f u. 1 f ua 1 D I A. I A m. D m A. f a. 1 f u. D m B ) D m A )(I m B. 1 f ua. 1 (I m A. log (I A. log f.
Supplementary Material Appendix 1 Here we show that independent inhibition by a single drug of two distinct steps (A and ) in the viral life cycle results in a non-linear median effect dose-response curve
More informationReverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review
pissn 2349-2910 eissn 2395-0684 REVIEW Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review Dinesh Bure, Department
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationNucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania
International Journal of Infectious Diseases (2009) 13, 81 89 http://intl.elsevierhealth.com/journals/ijid Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationNOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
More informationHIV-1 Protease and Reverse Transcriptase Mutation Patterns Responsible for Discordances Between Genotypic Drug Resistance Interpretation Algorithms
JAIDS Journal of Acquired Immune Deficiency Syndromes 33:8 14 2003 Lippincott Williams & Wilkins, Inc., Philadelphia Rapid Communication HIV-1 Protease and Reverse Transcriptase Mutation Patterns Responsible
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationFoscarnet salvage therapy for patients with latestage HIV disease and multiple drug resistance
Antiviral Therapy 11:561 566 Foscarnet salvage therapy for patients with latestage HIV disease and multiple drug resistance Ana Canestri 1, Jade Ghosn 1, Marc Wirden 2, Françoise Marguet 1, Nadine Ktorza
More informationPRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES
PRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES Mark A. Wainberg McGill University AIDS Centre Jewish General Hospital Montreal, Quebec,
More informationTenofovir Disoproxil Emtricitabine Mylan 300/200 Tenofovir disoproxil maleate 300 mg and Emtricitabine 200 mg
Tenofovir Disoproxil Emtricitabine Mylan 300/200 Tenofovir disoproxil maleate 300 mg and Emtricitabine 200 mg PRODUCT INFORMATION NAME OF THE MEDICINE The active substances in Tenofovir Disoproxil Emtricitabine
More information172R 172K TAM-2/172R TAM-2/172K. AZT concentration [nm] AZT concentration [nm] MgCl 2 2.5K 2.5K 5K 2.5K 5K 2.5K K 5K 2.5K 5K 2.5K 50 2.
5 5 5 5 A MgCl 2 172R 172K TAM-2/172R TAM-2/172K AZT concentration [nm] B 172R 172K TAM-2/172R TAM-2/172K AZT concentration [nm] ATP + ATP - Supplemental Figure 1. Primer extension of HIV-1 RT polymorphisms
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationHIV-1 DRUG RESISTANCE MUTATIONS IN CHILDREN WHO FAILED NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY
HIV-1 DRUG RESISTANCE MUTATIONS IN CHILDREN HIV-1 DRUG RESISTANCE MUTATIONS IN CHILDREN WHO FAILED NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY Somnuek Sungkanuparph 1, Nopporn
More informationICAAC/IDSA DC, Oct. 26, 2008
Tenofovir (TDF)- or Abacavir (ABC)-selected Minority Subpopulations in Viremic Subjects Detected by Ultra-deep Sequencing R. T. D Aquila 1, E. Rouse 2, J. Horton 2, A. Kheshti 1,3, S. Raffanti 1,3, K.
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationSubtle Decreases in Stavudine Phenotypic Susceptibility Predict Poor Virologic Response to Stavudine Monotherapy in Zidovudine-Experienced Patients
JAIDS Journal of Acquired Immune Deficiency Syndromes 31:121 127 2002 Lippincott Williams & Wilkins, Inc., Philadelphia Rapid Communications Subtle Decreases in Stavudine Phenotypic Susceptibility Predict
More informationAntiviral Therapy 2013; 18: (doi: /IMP2329)
Antiviral Therapy 2013; 18:213 219 (doi: 10.3851/IMP2329) Original article Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationCase Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital.
Case Study Dr Sarah Sasson Immunopathology Registrar HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital Case 1: Case 1: 45F in Cameroon Cameroon HIV+ Presents with cutaneous
More informationAntiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa
Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa Alana T Brennan, Kate Shearer, Mhairi Maskew, Prudence Ive, Ian Sanne, Matthew P Fox Health Economics
More informationTHE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner
More informationInvolvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors
JOURNAL OF VIROLOGY, July 2006, p. 7186 7198 Vol. 80, No. 14 0022-538X/06/$08.00 0 doi:10.1128/jvi.02084-05 Copyright 2006, American Society for Microbiology. All Rights Reserved. Involvement of Novel
More informationDolutegravir-Rilpivirine (Juluca)
Dolutegravir-Rilpivirine (Juluca) David H. Spach, MD Clinical Director, MW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated: November 30, 2017 ANTIRETROVIRAL
More informationCLAUDINE HENNESSEY & THEUNIS HURTER
HIV/AIDS/TB CLAUDINE HENNESSEY & THEUNIS HURTER KEY TERMS Do these sound familiar? What strange terms do you hear in the clinics? Any others to add?? HIV AIDS Viral Load & suppression CD4 count Regimen
More informationClinical Management of HIV Drug Resistance
Viruses 2011, 3, 347-378; doi:10.3390/v3040347 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Clinical Management of HIV Drug Resistance Karoll J. Cortez and Frank Maldarelli *
More informationTreatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand
Treatment experience in South Africa Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Overview South African Prevalence Adherence Combination ddi + d4t Nevirapine Hepatotoxicity
More informationPaediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University of Cape Town
A Public Sector Antiretroviral Treatment Programme for Treatment-Experienced Children and Adolescents in the Western Cape Province of South Africa Using Darunavir/Ritonavir-, Raltegravir- and Etravirine-Containing
More informationLa terapia dell infezione da HIV: passato, presente e futuro.
1 st Infectivology Today Paestum (SA) 14-15 maggio 2004 La terapia dell infezione da HIV: passato, presente e futuro. Prof. Adriano Lazzarin Università Vita-Salute San Raffaele, Milano Scuola di Specializzazione
More informationAntiretroviral Drugs
Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationHIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options
STRATEGIES FOR THIRD LINE HIV THERAPY issues to consider when faced with few drug options A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Most people living
More informationPersistent low level viraemia on third line ART
Persistent low level viraemia on third line ART Dr Richard Lessells XXVII International workshop on HIV drug resistance and treatment strategies October 2018 46-year old HIV-positive female HIV diagnosis
More informationClinical Management of Resistance. AMJ Wensing, MD, PhD
Clinical Management of Resistance AMJ Wensing, MD, PhD Changing treatment paradigm First Line Second Line? New First Line North America Western Europe: Eastern Europe Africa mix South America mix More
More informationHIV/AIDS CID 2003:37 (1 July) 113
MAJOR ARTICLE HIV/AIDS Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society USA Panel Martin S. Hirsch,
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationThe widespread use of antiretroviral therapy (ART) for the
ORIGINAL STUDIES Predictors of Virologic Failure and Genotypic Resistance Mutation Patterns in Thai Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor Based Antiretroviral Therapy Podjanee
More informationApplication for Inclusion of Emtricitabine On WHO Model List of Essential Medicines. Submitted By. Gilead Sciences, Inc. Foster City, California, USA
Application for Inclusion of Emtricitabine On Submitted By Foster City, California, USA 28 October 2004 Contact Person: Daniel E. Kates, M.D. Director Medical Communications 333 Lakeside Drive Foster City,
More informationHIV epidemiology since HIV in the United States. HIV Transmission
HIV epidemiology since 1999 8% increase in HIV diagnoses Men who have sex with men (MSM) increased 14% Heterosexual increased 10% IVDU decrease about 30% Young Black MSM 15% incidence HIV in the United
More informationNo part of this publication may be reproduced or photocopying. without the prior written permission. of the publisher
AIDS Reviews 2006;8:210-20 Clinical Implications of HIV Drug Resistance to Nucleoside and Nucleotide Reverse Transcriptase Inhibitors Anna Maria Geretti Royal Free Hospital and Royal Free & University
More informationHIV Drug Resistance: An Overview
Human Journals Review Article October 2015 Vol.:1, Issue:1 All rights are reserved by Suraj Narayan Mali et al. HIV Drug Resistance: An Overview Keywords: HIV drug resistance mechanism, Antiretroviral
More informationN348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance
N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance Soo-Huey Yap 1,2, Chih-Wei Sheen 3, Jonathan Fahey 1,4, Mark Zanin 1, David Tyssen 1, Viviane
More informationChetchotisakd et al. Materials and Methods
High Rate Multiple Drug Resistances in HIV-Infected Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Regimens in Thailand, Where Subtype A/E Is Predominant Ploenchan Chetchotisakd, MD, Siriluck
More information